Amgen, Relypsa and the art of the biotech-spinout-startup-restart
(UPDATED: See below.)
A common dilemma in biotech acquisitions is how to keep a startup’s entrepreneurial management happy and productive when they’ve just been assimilated by the Borg. The answer, often enough, is not to bother, and to let them spin out a new company with scientific “leftovers” that weren’t the point of the acquisition in the first place.
That’s more or less what Amgen has just done in launching Relypsa, a new Santa Clara, Calif., biotech just… Continue Reading